Chevy Chase Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History

Chevy Chase Trust Holdings, Inc.

$32.3 Billion
Q3 2024

A detailed history of Chevy Chase Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Chevy Chase Trust Holdings, Inc. holds 811,033 shares of NTLA stock, worth $10.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

811,033

Previous 1,042,625 22.21%

Holding current value

$10.6 Million

Previous $23.3 Million 28.57%

% of portfolio

0.05%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $4.57 Million - $6.34 Million	-231,592 Reduced 22.21%	811,033 $16.7 Million
Q2 2024 Jul 22, 2024	SELL	$20.02 - $27.22 $640,339 - $870,631	-31,985 Reduced 2.98%	1,042,625 $23.3 Million
Q1 2024 May 03, 2024	BUY	$23.82 - $32.8 $1.99 Million - $2.74 Million	83,435 Added 8.42%	1,074,610 $29.6 Million
Q4 2023 Jan 24, 2024	SELL	$23.16 - $32.34 $272,824 - $380,965	-11,780 Reduced 1.17%	991,175 $30.2 Million
Q3 2023 Oct 23, 2023	BUY	$31.62 - $45.78 $930,007 - $1.35 Million	29,412 Added 3.02%	1,002,955 $31.7 Million
Q2 2023 Jul 25, 2023	BUY	$34.58 - $46.03 $1.26 Million - $1.68 Million	36,477 Added 3.89%	973,543 $39.7 Million
Q1 2023 May 17, 2023	BUY	$33.3 - $44.82 $31.2 Million - $42 Million	937,066 New	937,066 $34.9 Million
Q4 2022 Feb 09, 2023	SELL	$33.21 - $62.69 $5.49 Million - $10.4 Million	-165,399 Reduced 14.54%	972,076 $33.9 Million
Q3 2022 Nov 04, 2022	BUY	$53.92 - $71.7 $5.46 Million - $7.25 Million	101,170 Added 9.76%	1,137,475 $63.7 Million
Q2 2022 Aug 10, 2022	SELL	$38.49 - $76.21 $787,620 - $1.56 Million	-20,463 Reduced 1.94%	1,036,305 $53.6 Million
Q1 2022 Apr 27, 2022	SELL	$58.27 - $118.99 $4.74 Million - $9.68 Million	-81,336 Reduced 7.15%	1,056,768 $76.8 Million
Q4 2021 Jan 31, 2022	SELL	$100.76 - $138.36 $2.08 Million - $2.85 Million	-20,628 Reduced 1.78%	1,138,104 $135 Million
Q3 2021 Oct 20, 2021	SELL	$132.37 - $176.78 $11.6 Million - $15.5 Million	-87,839 Reduced 7.05%	1,158,732 $155 Million
Q2 2021 Jul 20, 2021	SELL	$60.88 - $161.91 $4.74 Million - $12.6 Million	-77,858 Reduced 5.88%	1,246,571 $202 Million
Q1 2021 Apr 22, 2021	SELL	$46.59 - $83.68 $14.5 Million - $26.1 Million	-311,443 Reduced 19.04%	1,324,429 $106 Million
Q4 2020 Feb 12, 2021	SELL	$18.83 - $63.53 $3.17 Million - $10.7 Million	-168,384 Reduced 9.33%	1,635,872 $89 Million
Q3 2020 Nov 06, 2020	BUY	$17.47 - $24.93 $4.3 Million - $6.14 Million	246,093 Added 15.79%	1,804,256 $35.9 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $1.93 Million - $3.96 Million	173,351 Added 12.52%	1,558,163 $32.8 Million
Q1 2020 May 13, 2020	BUY	$9.44 - $15.58 $490,757 - $809,957	51,987 Added 3.9%	1,384,812 $16.9 Million
Q4 2019 Feb 12, 2020	BUY	$10.43 - $17.67 $814,144 - $1.38 Million	78,058 Added 6.22%	1,332,825 $19.6 Million
Q3 2019 Nov 20, 2019	BUY	$13.07 - $18.51 $2.02 Million - $2.87 Million	154,922 Added 14.09%	1,254,767 $16.8 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $1.99 Million - $2.64 Million	143,334 Added 14.99%	1,099,845 $18 Million
Q1 2019 May 13, 2019	BUY	$12.79 - $17.62 $3.34 Million - $4.6 Million	261,175 Added 37.56%	956,511 $14.7 Million
Q4 2018 Feb 14, 2019	SELL	$11.39 - $27.13 $531,776 - $1.27 Million	-46,688 Reduced 6.29%	695,336 $9.49 Million
Q3 2018 Oct 23, 2018	BUY	$25.78 - $32.6 $2.22 Million - $2.81 Million	86,142 Added 13.13%	742,024 $21.2 Million
Q2 2018 Aug 02, 2018	BUY	$20.02 - $30.79 $1.36 Million - $2.08 Million	67,714 Added 11.51%	655,882 $17.9 Million
Q1 2018 Apr 10, 2018	BUY	$19.43 - $34.95 $11.4 Million - $20.6 Million	588,168 New	588,168 $12.4 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $997M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.

Account

Chevy Chase Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History